Anti-inflammatory therapeutics market size to increase by USD 39.32 billion; North America to contribute 45% of market growth - Technavio

NEW YORK, Jan. 9, 2023 /PRNewswire/ -- The Anti-inflammatory Therapeutics Market by Application, Drug Class, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market size is forecast to grow by USD 39.32 billion between 2022 and 2027 at a CAGR of 6.7%. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download A PDF Sample Report

By region, the global anti-inflammatory therapeutics market is segmented into North America, Europe, Asia, and Rest of World. North America is estimated to contribute 45% to the growth of the global market over the forecast period. The sales of approved drugs for the treatment of conditions causing inflammation and the increasing prevalence of several associated risk factors are driving the growth of the anti-inflammatory therapeutics market in North America. Buy the report

The anti-inflammatory therapeutics market report includes information on the key products and recent developments of leading vendors, including:

• AbbVie Inc. - The company offers anti-inflammatory therapeutics with the latest technologies and platforms that aim to deliver better solutions.
• Alvogen Iceland ehf - The company offers anti-inflammatory therapeutics with the latest technologies to deliver better solutions.
• Amgen Inc. - The company offers anti-inflammatory therapeutics which brings therapies to millions of people with inflammatory diseases.
• Amneal Pharmaceuticals Inc. - The company offers anti-inflammatory therapeutics with products across a broad range of therapeutic areas including cardiovascular, central nervous system/pain, oncology, inflammation, and anti-infective.

The market is driven by factors such as the increase in off-label use, unmet needs for safer biologics for RA, and the availability of improved diagnostic modalities. However, the loss of patents is hindering market growth.

The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share among others. Request a Sample

Market Segmentation

• By application, the market is segmented into RA, psoriasis, and MS. The RA segment accounted for the largest share of the market in 2022.
• By geography, the market is segmented into North America, Europe, Asia, and Rest of World. North America held the largest share of the market in 2022.

Related Reports:

• The generic drugs market is estimated to grow at a CAGR of 7.11% between 2022 and 2027. The size of the market is forecasted to increase by USD 176.25 billion. The rising drug patent expirations are notably driving the market growth, although factors such as stringent regulations may impede the market growth.
• The antibiotics market is estimated to grow at a CAGR of 6.07% between 2022 and 2027. The size of the market is forecast to increase by USD 17,066.66 million. The rising prevalence of infectious diseases is notably driving the market growth, although factors such as the development of antibiotic-resistant strains may impede the market growth.

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

What are the key data covered in this anti-inflammatory therapeutics market report?

• CAGR of the market during the forecast period.
• Detailed information on factors that will drive the growth of the market between 2023 and 2027
• Precise estimation of the size of the anti-inflammatory therapeutics market and its contribution to the parent market.
• Accurate predictions about upcoming trends and changes in consumer behavior.
• Growth of the market across North America, Europe, Asia, and Rest of World.
• A thorough analysis of the market's competitive landscape and detailed information about vendors.
• Comprehensive analysis of factors that will challenge the growth of anti-inflammatory therapeutics market vendors.

Table of contents:

1 Executive Summary

• 1.1 Market overview 
• Exhibit 01: Executive Summary – Chart on Market Overview
• Exhibit 02: Executive Summary – Data Table on Market Overview
• Exhibit 03: Executive Summary – Chart on Global Market Characteristics
• Exhibit 04: Executive Summary – Chart on Market by Geography
• Exhibit 05: Executive Summary – Chart on Market Segmentation by Application
• Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
• Exhibit 07: Executive Summary – Chart on Incremental Growth
• Exhibit 08: Executive Summary – Data Table on Incremental Growth
• Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

• 2.1 Market ecosystem 
• Exhibit 10: Parent market
• Exhibit 11: Market Characteristics

3 Market Sizing

• 3.1 Market definition 
• Exhibit 12: Offerings of vendors included in the market definition

• 3.2 Market segment analysis 
• Exhibit 13: Market segments

• 3.3 Market size 2022

• 3.4 Market outlook: Forecast for 2022-2027 
• Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
• Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
• Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

• 4.1 Global anti-inflammatory therapeutics market 2017 - 2021
• Exhibit 18: Historic Market Size – Data Table on Global anti-inflammatory therapeutics market 2017 - 2021 ($ billion)

• 4.2 Application Segment Analysis 2017 - 2021
• Exhibit 19: Historic Market Size – Application Segment 2017 - 2021 ($ billion)

• 4.3 Drug class Segment Analysis 2017 - 2021
• Exhibit 20: Historic Market Size – Drug class Segment 2017 - 2021 ($ billion)

• 4.4 Geography Segment Analysis 2017 - 2021 
• Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)

• 4.5 Country Segment Analysis 2017 - 2021 
• Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

• 5.1 Five forces summary 
• Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

• 5.2 Bargaining power of buyers 
• Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

• 5.3 Bargaining power of suppliers 
• Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

• 5.4 Threat of new entrants 
• Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

• 5.5 Threat of substitutes 
• Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

• 5.6 Threat of rivalry 
• Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

• 5.7 Market condition 
• Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Application

• 6.1 Market segments 
• Exhibit 30: Chart on Application - Market share 2022-2027 (%)
• Exhibit 31: Data Table on Application - Market share 2022-2027 (%)

• 6.2 Comparison by Application 
• Exhibit 32: Chart on Comparison by Application
• Exhibit 33: Data Table on Comparison by Application

• 6.3 RA - Market size and forecast 2022-2027 
• Exhibit 34: Chart on RA - Market size and forecast 2022-2027 ($ billion)
• Exhibit 35: Data Table on RA - Market size and forecast 2022-2027 ($ billion)
• Exhibit 36: Chart on RA - Year-over-year growth 2022-2027 (%)
• Exhibit 37: Data Table on RA - Year-over-year growth 2022-2027 (%)

• 6.4 Psoriasis - Market size and forecast 2022-2027
• Exhibit 38: Chart on Psoriasis - Market size and forecast 2022-2027 ($ billion)
• Exhibit 39: Data Table on Psoriasis - Market size and forecast 2022-2027 ($ billion)
• Exhibit 40: Chart on Psoriasis - Year-over-year growth 2022-2027 (%)
• Exhibit 41: Data Table on Psoriasis - Year-over-year growth 2022-2027 (%)

• 6.5 MS - Market size and forecast 2022-2027
• Exhibit 42: Chart on MS - Market size and forecast 2022-2027 ($ billion)
• Exhibit 43: Data Table on MS - Market size and forecast 2022-2027 ($ billion)
• Exhibit 44: Chart on MS - Year-over-year growth 2022-2027 (%)
• Exhibit 45: Data Table on MS - Year-over-year growth 2022-2027 (%)

• 6.6 Market opportunity by Application 
• Exhibit 46: Market opportunity by Application ($ billion)

7 Market Segmentation by Drug Class

• 7.1 Market segments 
• Exhibit 47: Chart on Drug Class - Market share 2022-2027 (%)
• Exhibit 48: Data Table on Drug Class - Market share 2022-2027 (%)

• 7.2 Comparison by Drug Class 
• Exhibit 49: Chart on Comparison by Drug Class
• Exhibit 50: Data Table on Comparison by Drug Class

• 7.3 Anti-inflammatory biologicals - Market size and forecast 2022-2027 
• Exhibit 51: Chart on Anti-inflammatory biologicals - Market size and forecast 2022-2027 ($ billion)
• Exhibit 52: Data Table on Anti-inflammatory biologicals - Market size and forecast 2022-2027 ($ billion)
• Exhibit 53: Chart on Anti-inflammatory biologicals - Year-over-year growth 2022-2027 (%)
• Exhibit 54: Data Table on Anti-inflammatory biologicals - Year-over-year growth 2022-2027 (%)

• 7.4 Corticosteroids - Market size and forecast 2022-2027
• Exhibit 55: Chart on Corticosteroids - Market size and forecast 2022-2027 ($ billion)
• Exhibit 56: Data Table on Corticosteroids - Market size and forecast 2022-2027 ($ billion)
• Exhibit 57: Chart on Corticosteroids - Year-over-year growth 2022-2027 (%)
• Exhibit 58: Data Table on Corticosteroids - Year-over-year growth 2022-2027 (%)

• 7.5 NSAIDs - Market size and forecast 2022-2027
• Exhibit 59: Chart on NSAIDs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 60: Data Table on NSAIDs - Market size and forecast 2022-2027 ($ billion)
• Exhibit 61: Chart on NSAIDs - Year-over-year growth 2022-2027 (%)
• Exhibit 62: Data Table on NSAIDs - Year-over-year growth 2022-2027 (%)

• 7.6 Market opportunity by Drug Class 
• Exhibit 63: Market opportunity by Drug Class ($ billion)

8 Customer Landscape

• 8.1 Customer landscape overview 
• Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

• 9.1 Geographic segmentation 
• Exhibit 65: Chart on Market share by geography 2022-2027 (%)
• Exhibit 66: Data Table on Market share by geography 2022-2027 (%)

• 9.2 Geographic comparison 
• Exhibit 67: Chart on Geographic comparison
• Exhibit 68: Data Table on Geographic comparison

• 9.3 North America - Market size and forecast 2022-2027
• Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
• Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%)
• Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%)

• 9.4 Europe - Market size and forecast 2022-2027
• Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
• Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%)
• Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%)

• 9.5 Asia - Market size and forecast 2022-2027
• Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
• Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%)
• Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%)

• 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
• Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
• Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
• Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

• 9.7 US - Market size and forecast 2022-2027
• Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ billion)
• Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%)
• Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%)

• 9.8 Germany - Market size and forecast 2022-2027
• Exhibit 89: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 90: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
• Exhibit 91: Chart on Germany - Year-over-year growth 2022-2027 (%)
• Exhibit 92: Data Table on Germany - Year-over-year growth 2022-2027 (%)

• 9.9 UK - Market size and forecast 2022-2027
• Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ billion)
• Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
• Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
• Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)

• 9.10 Canada - Market size and forecast 2022-2027
• Exhibit 97: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
• Exhibit 98: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
• Exhibit 99: Chart on Canada - Year-over-year growth 2022-2027 (%)
• Exhibit 100: Data Table on Canada - Year-over-year growth 2022-2027 (%)

• 9.11 China - Market size and forecast 2022-2027
• Exhibit 101: Chart on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 102: Data Table on China - Market size and forecast 2022-2027 ($ billion)
• Exhibit 103: Chart on China - Year-over-year growth 2022-2027 (%)
• Exhibit 104: Data Table on China - Year-over-year growth 2022-2027 (%)

• 9.12 Market opportunity by geography 
• Exhibit 105: Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

• 10.1 Market drivers

• 10.2 Market challenges

• 10.3 Impact of drivers and challenges 
• Exhibit 106: Impact of drivers and challenges in 2022 and 2027

• 10.4 Market trends

11 Vendor Landscape

• 11.1 Overview

• 11.2 Vendor landscape 
• Exhibit 107: Overview on Criticality of inputs and Factors of differentiation

• 11.3 Landscape disruption 
• Exhibit 108: Overview on factors of disruption

• 11.4 Industry risks 
• Exhibit 109: Impact of key risks on business

12 Vendor Analysis

• 12.1 Vendors covered 
• Exhibit 110: Vendors covered

• 12.2 Market positioning of vendors 
• Exhibit 111: Matrix on vendor position and classification

• 12.3 AbbVie Inc. 
• Exhibit 112: AbbVie Inc. - Overview
• Exhibit 113: AbbVie Inc. - Product / Service
• Exhibit 114: AbbVie Inc. - Key news
• Exhibit 115: AbbVie Inc. - Key offerings

• 12.4 Alvogen Iceland ehf 
• Exhibit 116: Alvogen Iceland ehf - Overview
• Exhibit 117: Alvogen Iceland ehf - Product / Service
• Exhibit 118: Alvogen Iceland ehf - Key offerings

• 12.5 Amgen Inc. 
• Exhibit 119: Amgen Inc. - Overview
• Exhibit 120: Amgen Inc. - Product / Service
• Exhibit 121: Amgen Inc. - Key offerings

• 12.6 Amneal Pharmaceuticals Inc. 
• Exhibit 122: Amneal Pharmaceuticals Inc. - Overview
• Exhibit 123: Amneal Pharmaceuticals Inc. - Business segments
• Exhibit 124: Amneal Pharmaceuticals Inc. - Key news
• Exhibit 125: Amneal Pharmaceuticals Inc. - Key offerings
• Exhibit 126: Amneal Pharmaceuticals Inc. - Segment focus

• 12.7 Bayer AG 
• Exhibit 127: Bayer AG - Overview
• Exhibit 128: Bayer AG - Business segments
• Exhibit 129: Bayer AG - Key news
• Exhibit 130: Bayer AG - Key offerings
• Exhibit 131: Bayer AG - Segment focus

• 12.8 Bristol Myers Squibb Co. 
• Exhibit 132: Bristol Myers Squibb Co. - Overview
• Exhibit 133: Bristol Myers Squibb Co. - Product / Service
• Exhibit 134: Bristol Myers Squibb Co. - Key news
• Exhibit 135: Bristol Myers Squibb Co. - Key offerings

• 12.9 Eli Lilly and Co. 
• Exhibit 136: Eli Lilly and Co. - Overview
• Exhibit 137: Eli Lilly and Co. - Product / Service
• Exhibit 138: Eli Lilly and Co. - Key offerings

• 12.10 F. Hoffmann-La Roche Ltd 
• Exhibit 139: F. Hoffmann-La Roche Ltd - Overview
• Exhibit 140: F. Hoffmann-La Roche Ltd - Product / Service
• Exhibit 141: F. Hoffmann-La Roche Ltd - Key offerings

• 12.11 Ferring BV 
• Exhibit 142: Ferring BV - Overview
• Exhibit 143: Ferring BV - Product / Service
• Exhibit 144: Ferring BV - Key offerings

• 12.12 GlaxoSmithKline Plc 
• Exhibit 145: GlaxoSmithKline Plc - Overview
• Exhibit 146: GlaxoSmithKline Plc - Business segments
• Exhibit 147: GlaxoSmithKline Plc - Key offerings
• Exhibit 148: GlaxoSmithKline Plc - Segment focus

• 12.13 Johnson and Johnson 
• Exhibit 149: Johnson and Johnson - Overview
• Exhibit 150: Johnson and Johnson - Business segments
• Exhibit 151: Johnson and Johnson - Key news
• Exhibit 152: Johnson and Johnson - Key offerings
• Exhibit 153: Johnson and Johnson - Segment focus

• 12.14 Mylan N.V 
• Exhibit 154: Mylan N.V - Overview
• Exhibit 155: Mylan N.V - Product / Service
• Exhibit 156: Mylan N.V - Key offerings

• 12.15 Novartis AG 
• Exhibit 157: Novartis AG - Overview
• Exhibit 158: Novartis AG - Business segments
• Exhibit 159: Novartis AG - Key offerings
• Exhibit 160: Novartis AG - Segment focus

• 12.16 Pfizer Inc. 
• Exhibit 161: Pfizer Inc. - Overview
• Exhibit 162: Pfizer Inc. - Product / Service
• Exhibit 163: Pfizer Inc. - Key news
• Exhibit 164: Pfizer Inc. - Key offerings

• 12.17 Teva Pharmaceutical Industries Ltd. 
• Exhibit 165: Teva Pharmaceutical Industries Ltd. - Overview
• Exhibit 166: Teva Pharmaceutical Industries Ltd. - Business segments
• Exhibit 167: Teva Pharmaceutical Industries Ltd. - Key news
• Exhibit 168: Teva Pharmaceutical Industries Ltd. - Key offerings
• Exhibit 169: Teva Pharmaceutical Industries Ltd. - Segment focus

13 Appendix

• 13.1 Scope of the report

• 13.2 Inclusions and exclusions checklist 
• Exhibit 170: Inclusions checklist
• Exhibit 171: Exclusions checklist

• 13.3 Currency conversion rates for US$ 
• Exhibit 172: Currency conversion rates for US$

• 13.4 Research methodology 
• Exhibit 173: Research methodology
• Exhibit 174: Validation techniques employed for market sizing
• Exhibit 175: Information sources

• 13.5 List of abbreviations 
• Exhibit 176: List of abbreviations

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio